

# Biologic Studies Group -COVID-19, The University of Manchester

**First published:** 14/04/2010

**Last updated:** 19/02/2021

Institution

Educational Institution

## Institution identification

### PURI

<https://redirect.ema.europa.eu/resource/39566>

### Institution ID

39566

### Institution countries

United Kingdom

### Type of institution

Educational Institution

### Institution website

<https://sites.manchester.ac.uk/biologic-studies-group/>

### ENCePP partner

Yes

## Institution description

Biologic Studies Group: This group is part of the Versus Arthritis Centre for Epidemiology and hosts a number of UK national biologic and Other new targeted drug registers. The primary aim of these studies is to investigate the long-term safety of these newer therapies. The group consists of the following studies: 1. BSRBR-RA – The British Society for Rheumatology Biologics Register - Rheumatoid Arthritis 2. BADBIR – The British Association of Dermatologists' Biologic Interventions Register 3. BSPAR EN - Study of Enbrel in Children with JIA 4. BCRD - Arthritis Research UK Study of Biologics in Children with Rheumatic

Diseases5. BILAG BR - Biologics Register Prospective Cohort Study of Lupus6. BRAGGSS - Biologics in Rheumatoid Arthritis Genetics and Genomics Study SyndicateExpertise:The main areas of expertise include the epidemiology and genetics of rheumatic disease,pharmacovigilance and pharmacoepidemiology.

## Institution details

**Experience with collecting data directly from individual patients or respondents:**

Yes

---

**Interest in carrying out research that is funded by pharmaceutical companies:**

Yes

## Contact

Watson Kath



[kath.watson@manchester.ac.uk](mailto:kath.watson@manchester.ac.uk)